Outset Medical (NASDAQ:OM) General Counsel Sells $47,687.68 in Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John Brottem sold 9,314 shares of Outset Medical stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Outset Medical Stock Performance

OM stock opened at $5.11 on Friday. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. The firm has a market cap of $92.75 million, a P/E ratio of -0.39 and a beta of 2.07. Outset Medical, Inc. has a 12-month low of $3.10 and a 12-month high of $21.98. The stock’s 50 day simple moving average is $4.35 and its 200 day simple moving average is $10.89.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OM. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Outset Medical in a report on Tuesday, December 16th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. Finally, Stifel Nicolaus reduced their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Outset Medical currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Institutional Trading of Outset Medical

Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new stake in Outset Medical during the 2nd quarter valued at $34,000. Ameritas Investment Partners Inc. bought a new stake in shares of Outset Medical during the second quarter valued at about $35,000. BNP Paribas Financial Markets raised its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Outset Medical in the second quarter worth about $78,000. Finally, New York State Common Retirement Fund bought a new position in Outset Medical in the 2nd quarter valued at about $108,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.